TARGET AUDIENCE
Healthcare providers actively involved in the treatment and management of patients with breast cancer. This can include MDs/DOs, PAs, NPs, and registered nurses.
EDUCATIONAL OBJECTIVES
After attending this activity, the participant will demonstrate the ability to:
  1. Discuss the role of genetic and molecular testing and genetic counseling in the management of breast cancer
  2. Discuss known and potential targets and their associated therapeutic agents in the management of ER+ breast cancer and HER2+ breast cancer
  3. Discuss the role of CDK 4/6 kinase inhibitors in the treatment of breast cancer, including approved and emerging Agents
  4. Implement immunotherapy with checkpoint inhibitors in patients with breast cancer appropriately
  5. Evaluate novel drug classes being studied in the treatment of TNBC

AGENDA
April 13, 2019
8:00 am - 8:15 am Welcome and Opening Remarks Rodolfo Bordoni, MD
8:15 am - 9:00 am Session 1:
Is 21-Gene Expression-Guided Adjuvant Chemotherapy a new SOC? 		Cesar A. Santa-Maria, MD MSCI
9:00 am - 9:30 am Questions and Answers Faculty Panel/All Participants
9:30 am - 10:15 am Session 2:
Targeted Therapy of Triple Negative Breast Cancer 		Debasish Tripathy, MD
10:15 am - 11:00 am Questions and Answers Faculty Panel/All Participants
11:00 am - 12:30 pm Working Lunch/Roundtable Discussions Faculty Panel/All Participants
12:30 pm - 1:15 pm Session 3:
Therapeutic Strategies in HR-Positive Breast Cancer Resistant to Therapy 		Aditya Bardia, MD
1:15 pm - 1:45 pm Questions and Answers Faculty Panel/All Participants
1:45 pm - 2:00 pm Closing Remarks and Meeting Adjournment Rodolfo Bordoni, MD

The schedule of events and faculty are subject to change.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.